PMID- 25371386
OWN - NLM
STAT- MEDLINE
DCOM- 20160504
LR  - 20160511
IS  - 1942-7611 (Electronic)
IS  - 1942-7603 (Linking)
VI  - 7
IP  - 7
DP  - 2015 Jul
TI  - Development and validation of an LC-MS/MS method after chiral derivatization for 
      the simultaneous stereoselective determination of methylenedioxy-methamphetamine 
      (MDMA) and its phase I and II metabolites in human blood plasma.
PG  - 592-602
LID - 10.1002/dta.1740 [doi]
AB  - 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a racemic drug of abuse and 
      its two enantiomers are known to differ in their dose-response curves. The 
      S-enantiomer was shown to be eliminated at a higher rate than the R-enantiomer. 
      The most likely explanation for this is a stereoselective metabolism also claimed 
      in in vitro studies. Urinary excretion studies showed that the main metabolites 
      in humans are 4-hydroxy 3-methoxymethamphetamine (HMMA) 4-sulfate, HMMA 
      4-glucuronide and 3,4-dihydroxymethamphetamine (DHMA) 3-sulfate. For 
      stereoselective pharmacokinetic analysis of phase I and phase II metabolites in 
      human blood plasma useful analytical methods are needed. Therefore the aim of the 
      presented study was the development and validation of a stereoselective liquid 
      chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous 
      quantification of MDMA, 3,4-methylenedioxyamphetamine, DHMA, DHMA 3-sulfate, 
      HMMA, HMMA 4-glucuronide, HMMA 4-sulfate, and 4-hydroxy 3-methoxyamphetamine in 
      blood plasma for evaluation of the stereoselective pharmacokinetics in humans. 
      Blood plasma samples were prepared by simple protein precipitation and afterwards 
      all analytes were derivatized using N-(2,4-dinitro-5-fluorophenyl) L-valinamide 
      resulting in the formation of diastereomers which were easily separable on 
      standard reverse phase stationary phases. This simple and fast method was 
      validated according to international guidelines including specificity, recovery, 
      matrix effects, accuracy and precision, stabilities, and limits of 
      quantification. The method proved to be selective, sensitive, accurate and 
      precise for all tested analytes except for DHMA.
CI  - Copyright (c) 2014 John Wiley & Sons, Ltd.
FAU - Steuer, Andrea E
AU  - Steuer AE
AD  - Department of Forensic Pharmacology and Toxicology, Zurich Institute of Forensic 
      Medicine, University of Zurich, Switzerland.
FAU - Schmidhauser, Corina
AU  - Schmidhauser C
AD  - Department of Forensic Pharmacology and Toxicology, Zurich Institute of Forensic 
      Medicine, University of Zurich, Switzerland.
FAU - Liechti, Matthias E
AU  - Liechti ME
AD  - Psychopharmacology Research, Division of Clinical Pharmacology and Toxicology, 
      Department of Biomedicine and Department of Clinical Research, University 
      Hospital Basel, Basel, Switzerland.
FAU - Kraemer, Thomas
AU  - Kraemer T
AD  - Department of Forensic Pharmacology and Toxicology, Zurich Institute of Forensic 
      Medicine, University of Zurich, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20141104
PL  - England
TA  - Drug Test Anal
JT  - Drug testing and analysis
JID - 101483449
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Chromatography, Liquid/standards/trends
MH  - Humans
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*blood/*chemistry/metabolism
MH  - Reproducibility of Results
MH  - Stereoisomerism
MH  - Tandem Mass Spectrometry/*standards/trends
OTO - NOTNLM
OT  - LC-MS/MS analysis
OT  - MDMA
OT  - chiral derivatization
OT  - human blood plasma
OT  - phase II metabolites
EDAT- 2014/11/06 06:00
MHDA- 2016/05/05 06:00
CRDT- 2014/11/06 06:00
PHST- 2014/08/08 00:00 [received]
PHST- 2014/10/01 00:00 [revised]
PHST- 2014/10/02 00:00 [accepted]
PHST- 2014/11/06 06:00 [entrez]
PHST- 2014/11/06 06:00 [pubmed]
PHST- 2016/05/05 06:00 [medline]
AID - 10.1002/dta.1740 [doi]
PST - ppublish
SO  - Drug Test Anal. 2015 Jul;7(7):592-602. doi: 10.1002/dta.1740. Epub 2014 Nov 4.